Biotech Progress in Addressing Coronavirus, but It Takes Time
With the coronavirus creating havoc across the globe, researchers are rushing to find better treatment options and a cure. Our Head of Equities, Stephen Dover, and Portfolio Manager Evan McCulloch outline a few of the efforts the medical and scientific communities are taking to combat the virus.
The world’s medical and scientific community and health care, pharmaceutical and biotechnology companies are working more closely together than ever as our societies and economies seismically shift to new ways of engaging in life and commerce in response to the COVID-19 virus.
As global investors, we focus on data-driven and boots-on-the-ground research about COVID-19, and possible prevention, treatments and vaccines. Some of the positive steps the healthcare community is taking include:
- The virus responsible for COVID-19, “SARS-CoV-2,” also referred to as the “coronavirus,” has been identified and genetically sequenced and open-sourced for scientists to use.
- Most coronavirus data and research is public and open platform, enabling sharing of knowledge about prevention, treatments and vaccines.
- Our investment research teams are monitoring scores of possible vaccines for the SARS-CoV-2 coronavirus and efficacious prevention and treatments for COVID-19.
- Biotechnology and pharmaceutical companies globally are focused on prevention, treatments and vaccines for mitigating the coronavirus and COVID-19’s course.
Below is a short summary of five COVID-19 treatments in newsworthy research studies as of today, supplied by Evan McCulloch and our Franklin Equity Group health care and biotechnology research analysts.
Most Advanced Drugs for COVID-19
Portfolio Manager, Director of Equity Research
Franklin Equity Group®
Evan McCulloch, CFA